Literature DB >> 15383475

New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Jeffrey I Weitz1, Jack Hirsh, Meyer M Samama.   

Abstract

This article about new anticoagulant drugs is part of the seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The limitations of existing oral and parenteral anticoagulant agents have prompted a search for novel agents. Focusing on new anticoagulant drugs for the prevention and treatment of arterial and venous thrombosis, this article (1) reviews arterial and venous thrombogenesis, (2) discusses the regulation of coagulation, (3) describes the pathways for testing new anticoagulant agents, (4) describes new anticoagulant strategies focusing primarily on agents in phase II or III clinical testing, and (5) provides clinical perspective as to which of these new strategies is most likely to succeed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383475     DOI: 10.1378/chest.126.3_suppl.265S

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  New anticoagulants: anti IIa vs anti Xa--is one better?

Authors:  Kenneth A Bauer
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 2.  Direct thrombin inhibitors.

Authors:  Catherine J Lee; Jack E Ansell
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 3.  [Anticoagulation for secondary prevention: which drug in which situation?].

Authors:  J Weil; H Schunkert
Journal:  Internist (Berl)       Date:  2005-12       Impact factor: 0.743

4.  Pentasaccharide enhances the inactivation of factor Xa by antithrombin by promoting the assembly of a Michaelis-type intermediate complex. Demonstration by rapid kinetic, surface plasmon resonance, and competitive binding studies.

Authors:  Alireza R Rezaie
Journal:  Biochemistry       Date:  2006-04-25       Impact factor: 3.162

Review 5.  New anticoagulants for the prevention of venous thromboembolism.

Authors:  Cecilia Becattini; Alessandra Lignani; Giancarlo Agnelli
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

Review 6.  Thromboprophylaxis in elderly patients undergoing major orthopaedic surgery.

Authors:  Clifford W Colwell; Mary E Hardwick
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Dabigatran etexilate.

Authors:  Mark Sanford; Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Thrombin-Activatable Microbubbles as Potential Ultrasound Contrast Agents for the Detection of Acute Thrombosis.

Authors:  Jacques Lux; Alexander M Vezeridis; Kenneth Hoyt; Stephen R Adams; Amanda M Armstrong; Shashank R Sirsi; Robert F Mattrey
Journal:  ACS Appl Mater Interfaces       Date:  2017-10-20       Impact factor: 9.229

9.  A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin.

Authors:  Bruce S Stambler
Journal:  Int Arch Med       Date:  2013-10-31

10.  Identification of a novel anthocyanin synthesis pathway in the fungus Aspergillus sydowii H-1.

Authors:  Congfan Bu; Qian Zhang; Jie Zeng; Xiyue Cao; Zhaonan Hao; Dairong Qiao; Yi Cao; Hui Xu
Journal:  BMC Genomics       Date:  2020-01-08       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.